{"id":54,"date":"2017-03-15T08:40:58","date_gmt":"2017-03-14T23:40:58","guid":{"rendered":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/pathophysiology\/?page_id=54"},"modified":"2017-03-15T08:49:33","modified_gmt":"2017-03-14T23:49:33","slug":"2012-2","status":"publish","type":"page","link":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/pathophysiology\/works\/2012-2\/","title":{"rendered":"2012"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n
\n

\u25a0\u539f\u8457\u8ad6\u6587<\/p>\n

1. Funatsu T, Yamashita A, Kaku S, Iwatsuki Y, Asada Y. Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models. Thromb Haemost. 2012; 108: 896-902.<\/p>\n

2. Yamashita A, Nishihira K, Matsuura Y, Ito T, Kawahara K, Hatakeyama K, Hashiguchi T, Maruyama I, Yagi H, Matsumoto M, Fujimura Y, Kitamura K, Shibata Y, Asada Y. Paucity of CD34-positive cells and increased expression of high-mobility group box 1 in coronary thrombus with type 2 diabetes mellitus. Atherosclerosis. 2012; 224: 511-4.<\/p>\n

3. Matsuura Y, Hatakeyama K, Imamura T, Tsuruda T, Shibata Y, Kodama T, Kitamura K, Asada Y. Different distribution of Pentraxin 3 and C-reactive protein in coronary atherosclerotic plaques. J Atheroscler Thromb . 2012; 19: 837-45.<\/p>\n

4. Iwakiri T, Yano Y, Sato Y, Hatakeyama K, Marutsuka K, Fujimoto S, Kitamura K, Kario K, Asada Y. Usefulness of carotid intima-media thickness measurement as an indicator of generalized atherosclerosis: Findings from autopsy analysis. Atherosclerosis. 2012; 225: 359-62.<\/p>\n

5. Kuroki M, Nakada H, Yamashita A, Sawaguchi A, Uchino N, Sato S, Asanuma T, Asada Y, Tamura S. Loss of cellular viability in areas of ground-glass opacity on computed tomography images immediately after pulmonary radiofrequency ablation in rabbits. Jpn J Radiol. 2012; 30: 323-30.<\/p>\n

6. Nishihira K, Hatakeyama K, Kuriyama N, Nomura K, Fukushima Y, Inoue Y, Nakama T, Mine D, Sagara S, Ashikaga K, Matsuyama A, Kitamura K, Shibata Y, Asada Y. Presence of older thrombus in patients with late and very late drug-eluting stent thrombosis. J Cardiol. 2012; 59: 57-63.<\/p>\n

7. Sato Y, Ishibashi-Ueda H, Iwakiri T, Ikeda Y, Matsuyama T, Hatakeyama K, Asada Y. Thrombus components in cardioembolic and atherothrombotic strokes. Thromb Res. 2012; 130: 278-80.<\/p>\n

8. Hatakeyama K, Kaneko MK, Kato Y, Ishikawa T, Nishihira K, Tsujimoto Y, Shibata Y, Ozaki Y, Asada Y. Podoplanin expression in advanced atherosclerotic lesions of human aortas. Thromb Res. 2012; 129: e70-6.<\/p>\n

9. Tsuruda T, Hatakeyama K, Nagamachi S, Sekita Y, Sakamoto S, Endo GJ, Nishimura M, Matsuyama M, Yoshimura K, Sato Y, Onitsuka T, Imamura T, Asada Y, Kitamura K. Inhibition of development of abdominal aortic aneurysm by glycolysis restriction. Arterioscler Thromb Vasc Biol. 2012; 32: 1410-7.<\/p>\n

10. Satomi-Kobayashi S, Kinugasa M, Kobayashi R, Hatakeyama K, Kurogane Y, Ishida T, Emoto N, Asada Y, Takai Y, Hirata K, Rikitake Y. Osteoblast-like differentiation of cultured human coronary artery smooth muscle cells by bone morphogenetic protein endothelial cell precursor-derived regulator (BMPER). J Biol Chem. 2012; 287: 30336-45.<\/p>\n

11. Nakahata S, Saito Y, Marutsuka K, Hidaka T, Maeda K, Hatakeyama K, Shiraga T, Goto A, Takamatsu N, Asada Y, Utsunomiya A, Okayama A, Kubuki Y, Shimoda K, Ukai Y, Kurosawa G, Morishita K. Clinical significance of CADM1\/TSLC1\/IgSF4 expression in adult T-cell leukemia\/lymphoma. Leukemia. 2012; 26: 1238-46.<\/p>\n

12. Nagano M, Hatakeyama K, Kai M, Nakamura H, Yodoi J, Asada Y, Chijiiwa K. Nuclear expression of thioredoxin-1 in the invasion front is associated with outcome in patients with gallbladder carcinoma. HPB (Oxford). 2012; 14: 573-82.<\/p>\n

13. Umekita K, Kaneko Y, Yorita K, Hashiba Y, Matsuda M, Miyauchi S, Ueno S, Takajo I, Kusumoto N, Nagatomo Y, Marutsuka K, Okayama A. Arthropathy with infiltrate IgG4-positive plasma cells in synovium. Rheumatology (Oxford). 2012; 51: 580-2.<\/p>\n

14. Shide K, Kameda T, Shimoda H, Yamaji T, Abe H, Kamiunten A, Sekine M, Hidaka T, Katayose K, Kubuki Y, Yamamoto S, Miike T, Iwakiri H, Hasuike S, Nagata K, Marutsuka K, Iwama A, Matsuda T, Kitanaka A, Shimoda K. TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia. 2012; 26: 2216-23.<\/p>\n

15. Miyake K, Aratake Y, Sakaguchi T, Kiyoyama K, Kuribayashi T, Marutsuka K, Ohno E. Examination of CD26\/DPPIV, p53, and PTEN expression in thyroid follicular adenoma. Diagnostic Cytopathology. 2012; 40: 1047-53.<\/p>\n

16. Kanai T, Kuwabara M, Tanaka-Totoribe N, Nakamura E, Matsuo Y, Gamoh S, Suzuki A, Asada Y, Hisa H, Yamamoto R. Insulin Induces Internalization of the Plasma Membrane 5-Hydroxytryptamine(2A) (5-HT(2A)) Receptor in the Isolated Human Endothelium-Denuded Saphenous Vein via the Phosphatidylinositol 3-Kinase Pathway. J Pharmacol Sci. 2012; 118:178-85.<\/p>\n

\u25a0\u8457\u66f8<\/p>\n

1. Yamashita A, Asada Y. Pathology and pathophysiology of atherothrombosis: Virchow\u2019s triad revisited. In: Traditional and novel risk factors in atherothrombosis. Gaxiola (ed). Intech, 1-20. (2012)<\/p>\n

\u25a0\u7dcf\u8aac<\/p>\n

1. \u76db\u53e3\u6df8\u9999\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u8840\u5c0f\u677f\u3068\u52d5\u8108\u786c\u5316\u3001Pharma Medica\u30002012; 30: 21-6.<\/p>\n

2. \u5c71\u4e0b\u3000\u7be4\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u7b2cXI\u56e0\u5b50\u963b\u5bb3\u85ac\u3001\u5185\u79d1\u30002012; 101 : 79-82.<\/p>\n

3. \u7560\u5c71\u91d1\u592a\u3001\u9db4\u7530\u654f\u535a\u3001\u5cf6\u5c3e\u7fa9\u4e5f\u3001\u4e2d\u7530\u3000\u535a\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u5927\u52d5\u8108\u5468\u56f2\u708e\u3001\u5f8c\u8179\u819c\u7dda\u7dad\u75c7\u3001\u5fc3\u8840\u7ba1\u7cfb\u306e\u6162\u6027\u708e\u75c7\u3001\u5225\u518aBIO Clinica\u3000\u6162\u6027\u708e\u75c7\u3068\u75be\u60a3\u30002012; 1: 52-8.<\/p>\n

4. \u7560\u5c71\u91d1\u592a\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u611f\u67d3\u30fb\u708e\u75c7\u3068\u52d5\u8108\u786c\u5316\u2015\u4eba\u4f53\u75c5\u7406\u304b\u3089\u307f\u305f\u52d5\u8108\u786c\u5316\u3068\u8840\u6813\u75c7\u306b\u3064\u3044\u3066\u30fc\u3001\u8840\u6813\u6b62\u8840\u8a8c\u30002012; 23: 265-73.<\/p>\n

5. \u7560\u5c71\u91d1\u592a\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u52d5\u8108\u786c\u5316\u306e\u708e\u75c7\u2015\u30d2\u30c8\u306e\u75c5\u7406\u304b\u3089\u307f\u305f\u52d5\u8108\u786c\u5316\u306e\u9032\u5c55\u6a5f\u69cb\u306b\u3064\u3044\u3066\u30fc\u3001\u8840\u7ba1\u533b\u5b66\u30002012; 23: 265-73.<\/p>\n

6. \u7560\u5c71\u91d1\u592a\uff1a\u7cd6\u5c3f\u75c5\u306b\u5408\u4f75\u3059\u308b\u51a0\u52d5\u8108\u75c5\u5909\u306e\u7279\u5fb4\u3001\u3079\u3093\u3061\u306e\u30fc\u3068\u30002012; 23: 7.<\/p>\n

7. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u8840\u7ba1\u75c5\u7406\u304b\u3089\u307f\u305f\u8840\u6813\u5f62\u6210\u30e1\u30ab\u30cb\u30ba\u30e0\u3001\u8840\u6813\u6b62\u8840\u8a8c\u30002012; 23: 606-10.<\/p>\n

8. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u8840\u6813\u75c7\u306e\u5f62\u6210\u30e1\u30ab\u30cb\u30ba\u30e0\u306f\u3069\u3053\u307e\u3067\u89e3\u660e\u3055\u308c\u305f\u304b\uff1f\u3000\u5185\u79d12012; 110: 5-10.<\/p>\n

9. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u306e\u767a\u751f\u306b\u304a\u3051\u308b\u8840\u6813\u5f62\u6210\u6a5f\u5e8f\u306e\u75c5\u7406\u5f62\u614b\u3001\u9855\u5fae\u93e12012; 47: 87-91.<\/p>\n

10. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u51fa\u8840\u6027\u526f\u4f5c\u7528\u306e\u306a\u3044\u6297\u8840\u6813\u85ac\u3001medicina 2012; 49: 1046-8.<\/p>\n

11. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u9589\u585e\u6027\u52d5\u8108\u786c\u5316\u306e\u539f\u56e0\u30fb\u75c5\u7684\u610f\u7fa9\u3001\u65e5\u672c\u533b\u4e8b\u65b0\u58312012; 4583: 60-1.<\/p>\n

12. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u8840\u6813\u6027\u75be\u60a3\u306e\u767a\u75c7\u306b\u304a\u3051\u308b\u8840\u5c0f\u677f\u3068\u51dd\u56fa\u7cfb\u306e\u95a2\u4e0e\u3001Modern Physician 2012; 32: 708-11.<\/p>\n

13. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u52d5\u8108\u786c\u5316\u306e\u767a\u751f\u30fb\u9032\u5c55\u3068\u8840\u6813\u5f62\u6210\uff0d\u75c5\u7406\u50cf\u304b\u3089\u307f\u305f\u30a2\u30c6\u30ed\u30fc\u30e0\u8840\u6813\u75c7\u306e\u767a\u751f\u6a5f\u5e8f\uff0d\u3001\u52a0\u9f62\u76ae\u819a\u533b\u5b66\u30bb\u30df\u30ca\u30fc 2012; 7: 1-7.<\/p>\n

\u25a0\u75c7\u4f8b\u5831\u544a<\/p>\n

1. Yoshioka I, Marutsuka K, Igawa K, Nagata J, Yoshida M, Baba T, Ichiki T, Kondoh Y, Takamori K, Kashima K, Sakoda S.: Epidermal choristoma arising on the midline gingiva as a congenital epulis: A case report. Journal of Cranio-Maxillofacial Surgery. 2012; 40:812-4.<\/p>\n

2. Mizukami T, Obara M, Nishikomori R, Kawai T, Tahara Y, Sameshima N, Marutsuka K, Nakase H, Kimura N, Heike T, Nunoi H. Successful treatment with Infliximab for inflammatory colitis in a patient with X-linked anhidrotic ectodermal dysplasia with immunodeficiency. Journal of Clinical Immunology. 2012; 32: 39-49.<\/p>\n

3. Yamashita S, Ryu S, Miyata S, Uchinokura S, Yokogami K, Uehara H, Moriguchi S, Iwakiri T, Marustuka K, Ikenoue M, Sawa D, Yamada N, Kodama Y, Takeshima H. A huge intraventricular congenital anaplastic astrocytoma: case report with Histopathological and genetic consideration. Brain Tumor Pathology. 2012; 29: 107-12.<\/p>\n

4. Kawano N, Ono N, Yoshida S, Kuriyama T, Yamashita K, Beppu K, Shimao Y, Marutsuka K, Ueda Y, Ueda A.: Successful Treatment of Immunodeficiency-Associated EBV-Negative Lymphoproliferative Disorders in Rheumatoid Arthritis by Methotrexate Withdrawal and Prevention of its Relapse by Rituximab Administration. J Clin Exp Hematop. 2012; 52: 193-8.<\/p>\n

5. \u5742\u7530\u6075\u7406\u5b50\u3001\u4f50\u85e4\u52c7\u4e00\u90ce\u3001\u7560\u5c71\u91d1\u592a\u3001\u4e38\u585a\u6d69\u52a9\u3001\u80a5\u5f8c\u8cb4\u53f2\u3001\u897f\u5185\u4f38\u8f14\u3001\u9ad8\u6a4b\u5178\u5b50\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u5375\u5de3\u7d14\u7c8b\u578b\u7d68\u6bdb\u764c\u306e\uff11\u4f8b\u3001\u8a3a\u65ad\u75c5\u7406\u30002012; 29: 294-7.<\/p>\n

6. \u5869\u5c4b\u60a0\u6597\u3001\u4f50\u85e4\u52c7\u4e00\u90ce\u3001\u5c71\u4e0b \u7be4\u3001\u4e38\u585a\u6d69\u52a9\u3001\u5c71\u5185\u61b2\u4e4b\u3001\u798f\u5cf6\u548c\u5b50\u3001\u4e0a\u68ee\u7167\u4ee3\u3001\u9bab\u5cf6 \u6d69\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u5375\u5de3\u7c98\u6db2\u56a2\u80de\u817a\u816b\u3088\u308a\u767a\u751f\u3057\u305f\u5927\u7d30\u80de\u795e\u7d4c\u5185\u5206\u6ccc\u764c\u306e1\u4f8b\u3001\u8a3a\u65ad\u75c5\u7406\u30002012; 29: 146-9.<\/p>\n

7. \u76db\u53e3\u6df8\u9999\u3001\u4e38\u585a\u6d69\u52a9\u3001\u6d45\u7530\u7950\u58eb\u90ce\u3001\u524d\u4e45\u4fdd\u7406\u6075\u3001\u6301\u7530\u8015\u4ecb\u3001\u702c\u6238\u5c71\u5145\uff1a\u826f\u6027\u985e\u4e0a\u76ae\u69d8\u672b\u68a2\u795e\u7d4c\u9798\u816b\u760d\u306e1\u4f8b\u3001\u8a3a\u65ad\u75c5\u7406\u30002012; 29: 264-7.<\/p>\n

8. \u4f50\u85e4\u52c7\u4e00\u90ce\u3001\u9bab\u5cf6\u76f4\u6a39\u3001\u7560\u5c71\u91d1\u592a\u3001\u4e38\u585a\u6d69\u52a9\u3001\u4e0a\u68ee\u7167\u4ee3\u3001\u798f\u5cf6\u548c\u5b50\u3001\u5c71\u5185\u61b2\u4e4b\u3001\u9bab\u5cf6\u6d69\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u201d\u6d78\u6f64\u6027\u5fae\u5c0f\u4e73\u982d\u72b6\u817a\u764c\u69cb\u9020\u201d\u3092\u4f34\u3046\u5b50\u5bae\u4f53\u764c\u306e\u4e00\u4f8b\u3001\u65e5\u672c\u5a66\u4eba\u79d1\u75c5\u7406\u5b66\u4f1a\u8a8c\u30002012; 3: 81-3.<\/p>\n

9. \u9bab\u5cf6\u76f4\u6a39\u3001\u4e38\u585a\u6d69\u52a9\u3001\u4e0b\u6751\u8cb4\u5b8f\u3001\u8cc0\u672c\u654f\u884c\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1aHigh grade prostatic intraepithelial neoplasia, small cell neuroendocrine variant \u3092\u4f34\u3063\u305f\u524d\u7acb\u817a\u764c\u306e\u4e00\u4f8b\u3001\u8a3a\u65ad\u75c5\u7406\u30002012; 29: 39-43.<\/p>\n

10. \u7dbe\u90e8\u8cb4\u5178\u3001\u5bcc\u7530\u96c5\u6a39\u3001\u76db\u53e3\u6df8\u9999\u3001\u4e38\u585a\u6d69\u52a9\u3001\u6e05\u6c34\u54f2\u54c9\uff1a\u8853\u524d\u8a3a\u65ad\u304c\u56f0\u96e3\u3067\u3042\u3063\u305f\u5bfe\u5074\u80ba\u8ee2\u79fb\u3092\u4f34\u3046\u80ba\u985e\u57fa\u5e95\u7d30\u80de\u764c\u306e\uff11\u5207\u9664\u4f8b\u3001\u65e5\u672c\u547c\u5438\u5668\u5916\u79d1\u5b66\u4f1a\u96d1\u8a8c\u30002012; 26: 439-43.<\/p>\n

11. \u65b0\u752b\u6b66\u4e5f\u3001\u5185\u4e4b\u5009\u4fca\u6717\u3001\u6a2a\u4e0a\u8056\u8cb4\u3001\u4e0a\u539f\u4e45\u751f\u3001\u4e38\u585a\u6d69\u52a9\u3001\u798f\u5cf6 \u525b\u3001\u5869\u898b\u4e00\u525b\u3001\u4eac\u697d \u683c\u3001\u5c0f\u7389\u9686\u7537\u3001\u77e2\u91ce\u8cb4\u5fb3\u3001\u7af9\u5cf6\u79c0\u96c4\uff1a\u539f\u767a\u6027\u8133\u816b\u760d\u3068\u306e\u9451\u5225\u306b\u82e6\u616e\u3057\u305ftumefactive multiple sclerosis\u306e1\u4f8b\u3001\u8133\u795e\u7d4c\u5916\u79d1\u30b8\u30e3\u30fc\u30ca\u30eb\u30002012; 21: 625-30.<\/p>\n<\/div>\n<\/article>\n<\/div>\n<\/section>\n

\n